Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration

Area of Science:

• Bone Biology and Metabolism
• Endocrinology
• Immunology

Background:

• Sclerostin (SOST) inhibits Wnt signaling, negatively impacting bone formation and mineral acquisition.
• The therapeutic potential of SOST inhibition, particularly via vaccination, for estrogen deficiency-induced bone loss remains largely unexplored.

Purpose of the Study:

• To investigate the efficacy of a novel SOST-Fc fusion protein vaccination in ameliorating bone deterioration caused by estrogen deficiency.
• To elucidate the molecular mechanisms underlying SOST-Fc's protective effects on bone metabolism.

Main Methods:

• Generation of a SOST-Fc fusion protein combining a SOST peptide with an IgG Fc fragment.
• Administration of SOST-Fc to an ovariectomized mouse model to assess its impact on bone mineral density, microarchitecture, and mechanical strength.
• In vitro studies using osteoblast cultures to evaluate the effect of anti-SOST serum on SOST-induced inhibition.
• Analysis of key bone formation and resorption markers, Wnt signaling pathway components, and histopathological changes.

Main Results:

• SOST-Fc vaccination successfully generated anti-SOST antibodies, reduced serum SOST levels, and attenuated SOST's inhibitory effects on osteogenic gene expression.
• Treatment increased bone formation markers (osteocalcin) and decreased resorption markers (CTX-1, TRAP5b).
• SOST-Fc significantly improved bone mineral density, trabecular bone characteristics, and mechanical strength in femurs and lumbar spines, counteracting ovariectomy-induced deterioration.
• Histological analysis revealed improved bone accretion, reduced osteoclast surface, and normalized marrow fat content in SOST-Fc treated mice.
• SOST-Fc therapy upregulated osteoprotegerin and Wnt signaling components (Wnt3a, β-catenin, TCF4) while downregulating receptor activator of nuclear factor-κB ligand (RANKL).

Conclusions:

• Blockade of SOST action via SOST-Fc vaccination effectively restores Wnt signaling balance, harmonizing bone formation and resorption.
• SOST-Fc demonstrates significant therapeutic potential in preventing and treating osteoporosis resulting from estrogen deficiency.
• This study establishes SOST-Fc fusion protein as a promising molecular therapeutic candidate for osteoporotic disorders.